Literature DB >> 9295238

Expression of MT-3 mRNA in human kidney, proximal tubule cell cultures, and renal cell carcinoma.

J G Hoey1, S H Garrett, M A Sens, J H Todd, D A Sens.   

Abstract

The human metallothionein 3 (MT-3) gene has recently been identified and characterized as a brain-specific MT having growth inhibitory activity for neuronal cells. One objective of the present study was to determine if MT-3 is brain-specific or also present in the renal system, a site for chronic toxicity due to heavy metal exposure. Using RT-PCR methodology, MT-3 mRNA was shown to be expressed in the human renal system at levels below mRNA for the beta-actin gene. MT-3 mRNA was shown to be expressed in all samples obtained from both the developing and adult renal systems, from 20 weeks of fetal age to 72 years. Cultures of human proximal tubule (HPT) cells were used to determine if MT-3 mRNA expression is influenced by metal exposure. Exposure of HPT cells to either Zn2+ or Cd2+ resulted in an early (within 24 h), but unsustained increase in MT-3 mRNA. The demonstration of MT-3 mRNA expression in the kidney indicates that MT-3 may play an important early role in the response of the cell to metal exposure. MT-3 mRNA expression was also examined in tissues and cells from three cases of renal cell carcinoma. MT-3 was found to be expressed in all three cases at levels similar to those found for normal kidney, providing evidence that MT-3 mRNA expression is not altered in this cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295238     DOI: 10.1016/s0378-4274(97)00049-0

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  24 in total

1.  Differentiation- and polarization-dependent zinc tolerance in Caco-2 cells.

Authors:  Nina Zemann; Adolf Zemann; Petra Klein; Ibrahim Elmadfa; Manfred Huettinger
Journal:  Eur J Nutr       Date:  2010-11-20       Impact factor: 5.614

2.  Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis.

Authors:  M A Sens; S Somji; S H Garrett; C L Beall; D A Sens
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 3.  Drug resistance in lung cancer.

Authors:  Manish Shanker; David Willcutts; Jack A Roth; Rajagopal Ramesh
Journal:  Lung Cancer (Auckl)       Date:  2010-05-08

4.  Differential fluorescence labeling of cysteinyl clusters uncovers high tissue levels of thionein.

Authors:  Y Yang; W Maret; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

5.  Metallothioneins and brain injury: What transgenic mice tell us.

Authors:  Juan Hidalgo
Journal:  Environ Health Prev Med       Date:  2004-05       Impact factor: 3.674

Review 6.  Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes.

Authors:  Sook-Jeong Lee; Jae-Young Koh
Journal:  Mol Brain       Date:  2010-10-26       Impact factor: 4.041

7.  Reaction of human metallothionein-3 with cisplatin and transplatin.

Authors:  Andrei V Karotki; Milan Vasák
Journal:  J Biol Inorg Chem       Date:  2009-06-18       Impact factor: 3.358

8.  Quantitation of human metallothionein isoforms: a family of small, highly conserved, cysteine-rich proteins.

Authors:  Aaron A Mehus; Wallace W Muhonen; Scott H Garrett; Seema Somji; Donald A Sens; John B Shabb
Journal:  Mol Cell Proteomics       Date:  2014-02-03       Impact factor: 5.911

9.  Role of metallothioneins in benign and malignant thyroid lesions.

Authors:  Bartosz Pula; Pawel Domoslawski; Marzena Podhorska-Okolow; Piotr Dziegiel
Journal:  Thyroid Res       Date:  2012-12-28

10.  Differences in the epigenetic regulation of MT-3 gene expression between parental and Cd+2 or As+3 transformed human urothelial cells.

Authors:  Seema Somji; Scott H Garrett; Conrad Toni; Xu Dong Zhou; Yun Zheng; Amornpan Ajjimaporn; Mary Ann Sens; Donald A Sens
Journal:  Cancer Cell Int       Date:  2011-02-08       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.